S1PR1 and neoplasm: Given that S1PR1 and pSTAT3 closely co-operate during inflammatory and immunologic processes and neoplasms, the S1PR1/pSTAT3 risk category was developed to help stratify the risk of rituximab-treated DLBCL patients using immunohistochemistry for S1PR1 and pSTAT3.